The PI3-kinase/Akt pathway is an important cell survival pathway that is deregulated in the majority of human cancers. Despite the apparent druggability of several kinases in the pathway, no specific catalytic inhibitors have been reported in the literature. The authors describe the development of a fluorometric imaging plate reader (FLIPR)-based Akt1 translocation assay to discover inhibitors of Akt1 activation. Screening of a diverse chemical library of 45,000 compounds resulted in identification of several classes of Akt1 translocation inhibitors. Using a combination of classical in vitro assays and translocation assays directed at different steps of the Akt pathway, the mechanisms of action of 2 selected chemical classes were further defined. Protein translocation assays emerge as powerful tools for hit identification and characterization. (Journal of Biomolecular Screening 2005:20-29) 
INTRODUCTION

T
HE RECENT USE OF FUNCTIONAL GENOMICS in target identification and validation has generated a large number of attractive drug targets that are intractable by normal high-throughput screening (HTS) methods. There is therefore a growing need for novel screening methods that yield information different from more traditional screening parameters such as binding or catalytic activity. One of the most important aspects of protein function is subcellular localization, but this parameter has been exceedingly difficult to measure at high throughput, making it difficult to use as a primary screening output. With the introduction of new highcontent screening (HCS) systems, as well as our pioneering Redistribution drug discovery concept, this goal is now within reach, [1] [2] [3] [4] [5] and protein translocation assays with medium to high throughput (25,000 data points per day) have been devised. However, due to the specialized nature and the high acquisition costs of the HCS equipment and the very limited number of truly high-throughput HCS platforms in use within the industry, there is still a need for new methods that allow the formatting of Redistribution assays on more traditional equipment such as fluorometric imaging plate readers (FLIPRs).
One of the hallmarks of cancer cells is the ability to evade the control mechanisms that would otherwise induce apoptosis. 6 One of the major cellular prosurvival pathways is the PI3-K/Akt pathway. The importance of this pathway in human cancer cell survival is underscored by the fact that this pathway is deregulated in more than 50% of human cancers. 7 Most often, this is due to loss of the tumor suppressor PTEN, which, in turn, leads to constitutively activated Akt. Activation of the PI3-K/Akt pathway is a multistep process. First, growth factors, through their receptors, activate the enzyme PI3-K, which generates the phospholipids PI(3,4)P 2 and PI(3,4,5)P 3 within the plasma membrane. These phospholipids are broken down by PTEN, and as predicted, loss of PTEN leads to elevated levels of PI(3,4)P 2 and PI(3,4,5)P 3 . One function of PI(3,4)P 2 and PI(3,4,5)P 3 is to attract Akt to the plasma membrane by binding directly to the pleckstrin homology (PH) domain of Akt. Once at the membrane, Akt is activated by phosphorylation on 2 discrete sites by the kinases PDK1 and PDK2. PDK1 itself is a PH domain-containing protein and is recruited to the membrane following PI3-K activation in a manner similar to Akt. 8 The identity of PDK2 has yet to be fully established, although several candidates have been proposed. 9 Following activation at the mem-brane, Akt phosphorylates a number of cellular proteins involved in the regulation of cell proliferation, growth, and survival. The central position of Akt in the cell survival network makes it an attractive target for anticancer therapy. The present study aimed to develop a screening assay to identify compounds that inhibit Akt1 plasma membrane translocation and therefore activation by PDK1 and PDK2. This assay was used to screen a diverse set of 45,000 compounds from which several Akt1 pathway antagonists were identified. Preliminary characterization of the Akt1 antagonists indicates that the Akt1 translocation assay is capable of identifying compounds with both established and novel mechanisms of action within the PI3-K/Akt pathway.
MATERIALS AND METHODS
Plasmids
Btk (accession X58957) amino acids (aa) 1 to 180 were cloned via PCR with gene-specific primers from pooled cDNA libraries from the human spleen, testis, and thymus (Clontech, Palo Alto, CA). Gateway recombination sequences (Invitrogen Corporation, Carlsbad, CA) attached to these primers were used to shuttle the fragment into a Gateway donor vector pDONR™207 (Invitrogen). After being fully sequenced, the fragment was shuttled into a Gateway destination vector (Invitrogen) constructed from a eukaryotic cytomegalovirus promoter-based expression vector (EGFP N2-pCORON1000) (Amersham Biosciences, Buckinghamshire, UK). This created a Btk (aa1-180)-EGFP fusion plasmid. Correct recombination was verified by sequencing.
The Akt1 coding sequence (accession M63167) was PCR amplified from HeLa and human spleen cDNA libraries (Stratagene, La Jolla, CA). Added to the primers were 5′ XhoI and 3′ BamHI sites. After digesting the PCR product with XhoI and BamHI, the fragment was cloned into vector pEGFP-N1 (Clontech) digested with XhoI and BamHI. This created an Akt1-EGFP fusion plasmid that was verified by sequencing across the entire Akt1 sequence.
The Akt1-PH domain (aa 1-138) was excised from the Akt1-EGFP fusion plasmid using the 5′ XhoI and 3′ MscI restriction sites and ligated into vector pEGFP-N1 (Clontech) digested with XhoI and SmaI. The resulting Akt1-PH (aa 1-138)-EGFP fusion plasmid was subsequently sequenced to verify correct insertion.
The FOXO1 coding sequence (accession AF032885) was PCR amplified from a pool of human brain, fetus, testis, lung carcinoma, and leukemia cDNA (Clontech). The PCR product was cloned into the pENTR/D-TOPO ® vector and the entire insert sequenced. The FOXO1 coding sequence was then recombined into the EGFP N2-pCORON1000 destination vector, creating a FOXO1-EGFP fusion plasmid. Correct recombination was verified by sequencing.
All fusion constructs had an optimal Kozak sequence, ACC, inserted in front of the start codon. Primer sequences are available upon request.
Cells and stable transfections
CHOhIR cells 10 were cultured in Ham's F-12 Nutrient Mixture containing Glutamax-1 (Invitrogen) supplemented with 10% fetal bovine serum (FBS) (Biochrome KG, Berlin, Germany) and 1% penicillin-streptomycin (Invitrogen). U2OS cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with Glutamax-1 (Invitrogen) supplemented with 10% FBS and 1% penicillinstreptomycin. Jurkat E6-1 cells were cultured in RPMI 1640 medium with Glutamax-1 (Invitrogen) supplemented with 10% FBS and 1% penicillin-streptomycin. CHOhIR and U2OS cells were stably transfected with plasmids using the FuGene6 reagent (Roche Diagnostics Corporation, Indianapolis, IN) and maintained with 0.5 mg/mL Geneticin/G418 (Invitrogen). Stable transfectants were FACS sorted or cloned to obtain a homogeneous population of cells. CHOhIR cells stably expressing EGFPAkt1 were FACS sorted and cloned to establish CHOhIR EGFPAkt1 cl. 12. CHOhIR Btk-EGFP and EGFP-Akt1-PH were established by FACS sorting of CHOhIR cells stably expressing Btk-EGFP and EGFP-Akt1-PH, respectively. U2OS cells stably expressing FOXO1-EGFP were FACS sorted and cloned to establish U2OS FOXO1-EGFP GS cl. 1. The cells were cultured in a humidified incubator at 37°C and 5% CO 2 and were passaged twice weekly by resuspension with 0.25% trypsin/0.53 mM EDTA solution (Invitrogen) for 3 min at room temperature (RT). All cell lines tested negative for Mycoplasma.
Akt1 FLIPR assay
CHOhIR EGFP-Akt1 cl. 12 cells were used for primary screening. The screening assay was performed in black, clear-bottom 96-well Packard Viewplates (Packard Bioscience Company, Meriden, CT). Cells were seeded in culture medium at a density of 50,000 cells per well and incubated for 48 h at 37°C in a humidified CO 2 incubator. Prior to assay, the cells were washed 3 times in KrebsRinger-Wollheim (KRW) buffer (140 mM NaCl, 3.6 mM KCl, 0.5 mM NaH 2 PO 4 •H 2 O, 0.5 mM MgSO 4 •7H 2 O, 1.5 mM NaHCO 3 , 6 mM D-glucose, 1.5 mM CaCl 2 , 10 mM HEPES [pH 7.4]) containing 20 µM Acid Red 88 (AR88) (all from Sigma-Aldrich, St. Louis, MO), followed by equilibration for 15 min at 37°C.
Insulin-mediated EGFP-Akt1 plasma membrane translocation was monitored using a FLIPR (Molecular Devices Corporation, Sunnyvale, CA). The presence of AR88 in the assay buffer quenches EGFP fluorescence associated with the plasma membrane to a higher degree than cytoplasmic EGFP fluorescence. Using this method, plasma membrane translocation was measured as a decrease in fluorescence intensity.
100× solution in KRW buffer and was made fresh every 2 h. Because wortmannin is relatively unstable in aqueous solutions, it was necessary to use a higher concentration of wortmannin as a positive control in the FLIPR assay than in the Redistribution assays, in which the wortmannin control was a DMSO solution. Use of the 500-nM wortmannin solution resulted in 100% inhibition of Akt1 translocation over a full 2-h period. Addition of reagents was performed in FLIPR to all wells simultaneously. FLIPR settings were as follows: sample interval 3 sec, 0.5-sec exposure, slit mask inserted.
Akt1, Akt1-PH, and Btk Redistribution ® assay
Measurements of cytoplasm-to-membrane translocation of the Akt1, Akt1-PH, and Btk Redistribution ® assays required highconfluence cell seeding to obtain a robust response. However, to analyze the data using the imaging software, a measurement of the fluorescence background level is essential; therefore, the EGFPexpressing cells were mixed with nongreen parental CHOhIR. The final concentration of library compounds was 12.5 µM. Then, 0.25% DMSO was used as a negative control (S 0 ), and 100 nM wortmannin (Calbiochem), which corresponds to 100% inhibition, was used as a positive control (S max ). Immediately after compound/control addition, human recombinant insulin (Sigma), prepared as a 4× solution in assay buffer, was added to all wells, with a final concentration of 40 nM. Cells were then incubated for 4 min at RT before being fixed with 4% formalin buffer (VWR International, West Chester, PA), washed 3 times with phosphate-buffered saline (PBS) (Invitrogen), and stained with 1 µM DRAQ5 (BioStatus, Leicestershire, UK) in PBS for a minimum of 30 min and read on an IN Cell Analyzer 3000 (Amersham Biosciences). A similar cell-seeding and assay procedure was used for the Akt1-PH and Btk Redistribution assays, except that the final concentration of insulin used was 300 nM.
FOXO1 Redistribution
® assays U2OS FOXO1-EGFP GS cl. 1 cells were seeded at a density of 6000 cells per well in black 96-well Packard Viewplates and incubated O/N at 37°C in a CO 2 incubator. Cells were washed 1× in assay buffer (DMEM with Glutamax-1 supplemented with 1% penicillin-streptomycin, and 5 mM HEPEs containing 1.4% FBS. The assay was initiated by adding 12.5 µM DMSO-diluted library compound prepared as 4× solutions in assay buffer. Then, 0.25% DMSO was used as a negative control (S 0 ), and 150 nM wortmannin, which corresponds to 100% inhibition, was used as a positive control (S max ). Cells were then incubated for 1 h at 37°C in a CO 2 incubator before being fixed with 4% formalin buffer, washed 3 times with PBS, and stained with 1 µM DRAQ5 in PBS for a minimum of 30 min and read on the IN Cell Analyzer 3000.
IN Cell Analyzer 3000 assay procedure
The assay plates were read on the IN Cell Analyzer 3000. The instrument was equipped with a 40× dry objective and a 488-nm EGFP excitation filter, a 633-nm DRAQ5 excitation filter, a 535nm/45nm bandwidth EGFP emission filter and a 695nm/55nm bandwidth DRAQ5 emission filter.
1 Neutral density filters were applied when appropriate. The plates were exposed for 1.5 ms, and a binning of 1 was used for the Akt1, Akt1-PH, and Btk Redistribution ® assays. Binning 2 was used for the FOXO1 Redistribution ® assay. The scan width and length were 0.745 nm and the slit width 30 µm.
To monitor the cytoplasm-to-membrane translocation, the images from the Akt1, Akt1-PH, and Btk Redistribution ® assays were analyzed using the IN Cell Analyzer 3000 Membrane Spot analysis module (MSP0). The MSP0 algorithm is designed to identify spots (i.e., bright objects) at the edge of the cell and is based on defining the DRAQ5-stained nuclei of cells. Once the nuclei were identified, the EGFP fluorescence intensity buildup at the perimeter of the cells could be identified using the MSP0 analysis parameters. The average area of identified spots per cell was calculated for each well and taken as a measurement of the cytoplasmto-membrane translocation of EGFP. The analysis parameters were optimized for each of the assays.
To monitor the cytoplasm-to-nucleus translocation with the IN Cell Analyzer 3000, the Trafficking Analysis Module 2 (TRF2) was used in the FOXO1 Redistribution ® assay. The TRF2 algorithm is designed to extract the nuclear and cytoplasmic EGFP intensity values and is based on defining the cells by the DRAQ5-stained nuclei. The capability of DRAQ5 to stain the cytoplasm of cells, although with a lower affinity than for the nuclei, is used in the TRF2 algorithm to define the cytoplasm. The EGFP fluorescence intensity in the nuclei and cytoplasm can then be measured by using the TRF2 analysis parameters. The nuclear-to-cytoplasm ratio is calculated for each well by the algorithm and taken as a measurement of the cytoplasm-to-nucleus translocation of EGFP.
Data analysis and calculations
Each compound was screened in singles. Data were only accepted if the Z′ factor was above or equal to 0.3. For each individual plate, the average raw activity and standard deviation (SD) were calculated for S 0 and S max (8 wells of each on every 96-well plate).
The Z′ factor was calculated from the S 0 and S max raw activity according to the following formula:
The percent activity (PCTACT) for each well was calculated relative to the positive control (S max ) from the raw activity in the following way:
For concentration-response determinations, a curve was fitted to the PCTACT values using GraphPad Prism 3.03 software (GraphPad Software, San Diego, CA), and when possible, an EC 50 value was calculated.
Western blot analysis
Jurkat cells were seeded at a density of 1.5 × 10 6 cells per well and incubated for 24 h before test compounds were added for 30 min. Cell pellets were collected after centrifugation at 1100 rpm for 5 min at RT and washed in ice-cold PBS before an additional centrifugation at 1100 rpm for 5 min at RT. Cells were then washed before being harvested using the Cytobuster Protein Extraction Reagent (Novagen, Madison, WI) cell lysis buffer according to the manufacturer's instructions. Then, 1% (v/v) serine/threonine protein phosphatase inhibitor cocktail 1 (Sigma) and 1% (v/v) protease inhibitor cocktail (Sigma) were added immediately before cell lysis, and the cell pellets were lysed for 10 min at RT. The supernatants were collected after centrifugation at 16,000g for 5 min at 4°C. 
RESULTS AND DISCUSSION
Identification of Akt pathway antagonists by HTS
To identify small-molecule antagonists of the Akt pathway, we established a mammalian cell-based assay. Chinese hamster ovary (CHO) cells stably expressing the human insulin receptor (CHO.hIR) were transfected with a plasmid encoding an Akt1-GFP fusion protein. Clones of CHO.hIR cells stably expressing Akt1-GFP were screened manually on a fluorescence microscope for their response to insulin, and a clone with a particularly robust Akt1 cytoplasm-to-plasma membrane translocation response was chosen for further analysis (referred to as clone 12). The assay was converted into an intensity-based assay to improve the throughput, based on the hypothesis that an increase in local GFP fluorophore concentration would occur when Akt1-GFP translocates from 3-dimensional space (broad cytoplasmic localization) to 2-dimensional space (plasma membrane localization), resulting in increased GFP-GFP fluorescence quenching and thus in a loss of apparent total GFP fluorescence intensity. We further reasoned that specific quenching of plasma membrane-localized GFP fluorescence might be attained using a nonpermeable fluorescence quencher such as AR88. To test these hypotheses, we seeded clone 12 cells in 96-well plates and measured total GFP fluorescence on a dynamic plate reader (Molecular Dynamics FLIPR) in response to insulin. As shown in Figure 1A , addition of insulin caused a sharp initial decline in fluorescence, which then leveled out to a constant lower level after 3 to 5 min. This lower level of fluorescence, representative of a population of Akt-GFP localized at the plasma membrane, remains relatively constant for at least 10 min (not shown). A representative concentration-response curve for insulin using the loss of total fluorescence after 3 min as a readout is shown in Figure 1B . To investigate whether the assay detected inhibitors of the Akt pathway, increasing concentrations of the PI3-K inhibitor wortmannin were added to cells that had been pretreated with insulin for 3 min. As shown in Figure 1C , wortmannin concentration-dependently reversed the loss of fluorescence intensity seen after insulin stimulation, with an apparent EC 50 value of 20 nM. This value is in good agreement with what has already been reported for wortmannin in other cell-based assays. 13 Using the assay system outlined above, we screened a diverse chemical library of 45,000 compounds at a concentration of 12.5 µM and isolated several putative Akt1 translocation antagonists. The distribution of hits according to their activity (100% activity refers to a maximal concentration of wortmannin) is shown in Figure 2A. To assess the quality of the screen, we included control wells on each 96-well plate and calculated the Z′ value 14 for all plates in the screen. A plot of Z′ values over the screening run is shown in Figure 2B . Based on the Z′ values, we believe that this Akt translocation assay is of sufficient quality to reliably identify Akt translocation inhibitors. In addition, 1 compound identified in the screen was LY294002, a known PI3-K inhibitor, further validating our screening approach (not shown).
Confirmation of hit compound activity
Although the screen yielded hit compounds from several chemical classes, for the remainder of this report, we focus on hits from 2 chemical classes with different modes of action. The structure of 3 hit compounds is shown in Figure 3A . Compound 1 is an analog of the general adenosine triphosphate (ATP)-competitive kinase inhibitor quercetin, 13 whereas compounds 2 and 3 are analogs of each other with a previously uncharacterized mode of action. Because the hit compounds were found in a non-imaging-based assay, fluorescence microscopy was used to confirm that these compounds do indeed inhibit Akt1 translocation. As shown in Figure  3B , compounds 1 to 3 all reverse the insulin-stimulated translocation of Akt1 to the plasma membrane. To quantify the effects of compounds 1 to 3 on Akt1 translocation, we developed a high-throughput imaging assay for the Amersham IN Cell Analyzer 3000 (see Materials and Methods for details), using wortmannin to validate the assay. As shown in Figure 3C , the EC 50 value for wortmannin (20 nM) corresponds well with that obtained in the plate reader assay (Fig. 1C) . We next determined the potencies of the hit compounds in the Akt imaging assay. As shown in Figure 3D , all the hit compounds inhibit the translocation of Akt1 in a concentration-dependent manner, with EC 50 values in the µM range.
Mechanism of action
Having isolated several chemical classes of Akt1 antagonists, we next sought to identify the mechanism of action of each compound class, using quantitative imaging assays to evaluate the plasma membrane translocation of several PH domain-containing proteins. The EC 50 value for wortmannin is 70 nM in the Akt1-PH assay and 150 nM in the Btk assay, respectively (not shown). Because the chemical structures of compounds 2 and 3 are very similar, we chose to focus on compound 3 for the mechanism-of-action studies. As demonstrated in Figure 4 , compound 1 inhibits the translocation of the isolated PH domains of Akt1 and Btk (not shown), with a potency similar to that of full-length Akt1 translocation. This suggests that compound 1 acts either by binding to PH domains with limited selectivity or by inhibiting one of the steps leading to PIP3 generation upstream of Akt1 translocation. Based on the similarity of compound 1 with the general ATP-competitive kinase inhibitor quercetin, compound 1 might be expected to act as an inhibitor of a kinase upstream of PIP3 generation. In favor of that hypothesis, compound 1 inhibits the catalytic activity of the class I PI3-K γ, with an EC 50 of approximately 5µM in an in vitro kinase assay (not shown), suggesting that it functions in our cell-based assays by inhibiting 1 or more class I PI3-K isoforms.
In contrast, compound 3 only inhibited the translocation of fulllength Akt1 but not the translocation of the isolated PH domain of Akt1 (Fig. 4) or Btk (not shown). Because the PH domain of Akt1 is the major determinant of Akt1 translocation, this result suggests that compound 3 inhibits Akt1 translocation by binding, at least in part, to a region of Akt1 outside of the PH domain and thereby indirectly affects the ability of the PH domain to facilitate plasma membrane translocation in response to PIP3 generation. Alternatively, compound 3 may bind directly to the PH domain of Akt1 in a fashion that is dependent on Akt1 sequences outside of the PH domain. Although this work was in progress, Barnett et al. 15 reported a series of compounds with close structural homology to compounds 2 and 3. They found that 1 class of (2,3)di-aromatequinoxalines inhibited the kinase activity of full-length Akt1 but not of an Akt1 mutant in which the PH domain had been deleted. Based on these data, we hypothesized that (2,3)di-aromatequinoxalines may bind to 2 weak binding sites on Akt1, 1 in the kinase domain and 1 in the PH domain. Binding to Akt1 causes both inhibition of kinase activation (through inhibition of plasma membrane translocation) and kinase activity (through direct binding to the kinase domain). In agreement with this hypothesis, compound 3 also inhibited the kinase activity of Akt1 (but not PDK1) in the in vitro kinase assays, with an EC 50 value of 12 µM (not shown).
Effect of Akt pathway antagonists on PI3K pathway components
Plasma membrane translocation of Akt1 leads to its activation by phosphorylation on T308 in the activation loop and S473 in the C-terminus of the protein. We wished to determine the effect of our pathway antagonists on the Akt1 activation state in Jurkat cells, which are PTEN negative and therefore have high constitutive Akt1 activity. 16 As shown in Figure 5 , both compound 1 and compound 3 inhibit the phosphorylation of Akt1 at both T308 and S473.
We then determined whether our Akt pathway antagonists would affect the cellular behavior of an Akt1 substrate using a quantitative imaging assay to measure nucleo-cytoplasmic shuttling of the transcription factor FOXO1 (FKHR).
17 FOXO1 and its isoforms FOXO3A and FOXO4 are phosphorylated by Akt1 on multiple serines/threonines, resulting in the inactivation of the FOXO protein by cytoplasmic retention due to the binding of 14-3-3 proteins to the phosphorylated FOXO residues. Cytoplasmic FOXO proteins translocate into the nucleus when the Akt pathway is turned off (e.g., by incubation in the presence of wortmannin; Fig. 6A ). Quantification of the wortmannin response reveals that wortmannin causes translocation of FOXO1 with a potency that is comparable to that of Akt1 translocation inhibition (cf. Fig. 6B and Fig. 1C ). Compounds 1 and 3 also induced nuclear translocation of FOXO1 (Fig. 6C) , with compound 1 being the most potent. As for wortmannin, there is good alignment of potencies for compound 1 in the different imaging assays. On the other hand, compound 3 is significantly less potent in the FOXO1 assay compared to the Akt1 assay. We do not at present understand the molecular basis for this difference, although one possibility is that other PI3-kinase-dependent FOXO1 regulators are present in the FOXO1 assay cell line. This would explain why upstream pathway inhibitors such as wortmannin and compound 1 are equally potent when assayed against Akt1 translocation and FOXO1 translocation, whereas Akt-specific inhibitors such as compound 3 are more efficient at inhibiting Akt1 translocation than at promoting FOXO1 translocation. One candidate for this parallel regulation of FOXO1 is SGK1, another FOXO1 kinase that is dependent on PI3-K activity. 18 Further experiments will be required to determine the relative contributions of Akt and SGK family kinases to FOXO1 regulation. 
3000 system more versatile than the FLIPR. Furthermore, imaging-based screening is truly high content in the sense that it allows simultaneous selection based on several criteria (such as toxicity, fluorescence of compound, etc.), only one of which may be the primary screening parameter. Conversely, high-throughput imaging systems have considerably higher costs of acquisition and maintenance compared to the FLIPR. We found similar throughputs for the Akt1 translocation assay when run on the FLIPR compared to the same assay on the IN Cell Analyzer 3000 imaging system (3000-5000 compounds per day in the 96-well format and 12,000-15,000 compounds per day in the 384-well format, although throughput on the IN Cell Analyzer 3000 system was considerably higher for other translocation events, such as nucleo-cytoplasmic transport).
To define the mechanism of action of the Akt pathway antagonists identified in the FLIPR screen, we employed a series of highthroughput imaging assays designed to intersect the pathway at multiple points. These suggest that compound 1 acts either as an upstream inhibitor in the pathway or as a general inhibitor of the PH domain function. Based on the structural homology with known inhibitors, as well as the activity of compound 1 in traditional in vitro kinase assays, it seems likely that compound 1 acts as an upstream inhibitor of the pathway by antagonizing the function of PI3-K. Compound 3 showed a more unique profile in our assay panel, inhibiting the translocation of full-length Akt1 but not the PH domains of Akt1 and Btk. In addition, compound 3 inhibited the kinase activity of Akt1 directly, suggesting that it binds to Akt1 in a way that compromises the functions of both the PH domain and the kinase domain. This is in agreement with kinase inhibition data of other (2,3)di-aromate-quinoxalines because these compounds were shown to inhibit the kinase activity of full-length Akt1 but not the isolated kinase domain. 15 Figure 7 summarizes our current understanding of the mechanism of action of compounds 1 and 3. We conclude that translocation assays, when employed as primary screening assays, can identify compounds with both expected and novel mechanisms of action (compounds 1 and 3, respectively). In addition, translocation assays directed at various levels of a signaling pathway provide a powerful tool for investigating the mechanism of action of novel compounds. It will be interesting to investigate the in vivo selectivity and function of our Akt1 pathway antagonists once we have developed more potent chemical derivatives.
FIG. 7.
Schematic showing the possible mechanism of action of compounds 1 and 3. Compound 1 most likely interferes with the generation of PIP3 through the direct inhibition of the catalytic activity of PI3-kinase (p110). Compound 3 possibly works by inhibiting both the pleckstrin homology (PH) domain and the catalytic domain of Akt1 (purple).
